Results
Bal Pharma Approves FY26 Results, Dividend, ESOP
Board approved audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026, with unmodified audit opinion.
Recommended a dividend of ₹1.20 per share (12%) subject to shar
